Research programme: Ebola virus therapeutics - Immunotech

Drug Profile

Research programme: Ebola virus therapeutics - Immunotech

Latest Information Update: 27 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunotech Laboratories
  • Class Proteins
  • Mechanism of Action Immunostimulants; Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Ebola virus infections

Most Recent Events

  • 21 Oct 2014 Ebola virus therapeutics licensed to Uldic Investments in Sub-Saharan West Africa
  • 21 Oct 2014 Early research in Ebola virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top